Established medicine
Approved uses are specific.
Sirolimus is an immunosuppressant with FDA-approved uses. Longevity is not an approved indication.
Rapamycin, without the shortcuts
A clearer view of a complicated molecule.
Separate established medicine, active human research, and unresolved longevity claims—then take better questions to a licensed clinician.
Primary sourcesNo product salesNo dosing advice
Evidence snapshotUpdated 2026
mTOR pathway
What do we actually know?
EstablishedApproved clinical uses
Being studiedHuman aging research
Not establishedHuman longevity benefit
Evidence categories are editorial summaries, not medical recommendations.
Research is not a prescription
01 / Evidence map
Three categories.
No blurred lines.
Use the status of the evidence—not the intensity of the marketing—to understand each claim.
Active research
Human aging studies are underway.
Researchers are studying mTOR inhibition in older adults, including safety, timing, and biological effects.
Open question
Healthspan benefit is unproven.
Animal findings do not establish that rapamycin extends human life or improves healthy aging.
02 / Clinician conversation guide
Good questions are safer than confident assumptions.
The guide helps readers discuss evidence, intended goals, individual risks, monitoring, interactions, and alternatives with an appropriately licensed clinician.
Open the conversation guide →01
What evidence applies to my goal?
02What risks or interactions matter for me?
03What would be monitored, and why?
03 / Source discipline
Start with the label. Then follow the research.
Our summaries begin with public, primary or authoritative sources: FDA labeling and safety materials, the National Institute on Aging, MedlinePlus, and registered human studies.
Review the source libraryThe editorial pledge
We will tell you what is established, what is being studied, and what remains unknown. We will not turn uncertainty into a sales pitch.